Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8530739 | 0.80 | MEN1 (0.48) | HTTKMT2AMEN1CA2CA4 | |
| SCHEMBL2309806 | 0.80 | MEN1 (0.48) | HTTKMT2AMEN1CA2CA4 | |
| SCHEMBL27651298 | 0.80 | HTT (0.48) | HTTKMT2AMEN1CA2CA4 | |
| SCHEMBL7526246 | 0.80 | HTT (0.48) | HTTKMT2AMEN1CA2CA4 | |
| Hydrochloric Acid SCHEMBL27627985 | 0.78 | MEN1 (0.46) | HTTKMT2AMEN1CA2CA4 | |
| SCHEMBL9386233 | 0.76 | SRC (0.43) | HTTKMT2AMEN1CA2CA4 | |
| SCHEMBL8370301 | 0.74 | HTT (0.59) | HTTKMT2AMEN1CA2CA4 | |
| Phosphoric Acid SCHEMBL1242659 | 0.72 | ALDH1A1 (0.50) | HTTKMT2AMEN1CA2CA4 | |
| Phosphoric Acid SCHEMBL29898200 | 0.72 | ALDH1A1 (0.50) | HTTKMT2AMEN1CA2CA4 | |
| SCHEMBL6748159 | 0.71 | POLB (0.39) | HTTKMT2AMEN1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024075736-A1 | NITROGEN-CONTAINING COMPOUND, COMPOSITION COMPRISING SAID NITROGEN-CONTAINING COMPOUND, AND MARKER FOR PREDICTING TUMOR GRADE | 学校法人関西医科大学 | 2024-04-11 | — | — | WO | disclosed |
| US-20080293701-A1 | 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-7329660-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2008-02-12 | — | — | US | disclosed |
| EP-1844002-A1 | 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-7115777-B2 | Amide derivatives as inhibitors of the enzymatic activity of renin | NOVARTIS AG (CH) | 2006-10-03 | — | — | US | disclosed |
| US-20060217388-A1 | Phthalazine derivatives for treating inflammatory diseases | BOLD GUIDO | 2006-09-28 | — | — | US | disclosed |
| WO-2006083924-A1 | 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | ELAN PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| EP-1165085-B1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| US-4595677-A | Substituted tetrapeptides | CIBA-GEIGY CORPORATION (US) | 1986-06-17 | — | — | US | disclosed |
| EP-0184550-A2 | 5-Amino-4-hydroxy valeryl amide derivatives | CIBA-GEIGY AG (CH) | 1986-06-11 | — | — | EP | disclosed |
| EP-0175570-A2 | Process for the preparation of aromatic-1,4-oxazepinones and thiones | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1986-03-26 | — | — | EP | disclosed |
| EP-0144290-A2 | Substituted ethylenediamine derivatives | CIBA-GEIGY AG (CH) | 1985-06-12 | — | — | EP | disclosed |
| EP-0143746-A2 | 5-Amino 4-hydroxy-valeryl-substituted derivatives | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | disclosed |
| US-4483977-A | TETRAMINOBIPHENYL AND ISOPHTHALIC ACID | CELANESE CORPORATION (US) | 1984-11-20 | — | — | US | disclosed |
| EP-0111266-A2 | Substituted tetrapeptides | CIBA-GEIGY AG (CH) | 1984-06-20 | — | — | EP | disclosed |
| US-4452967-A | MELT POLYMERIZATION OF AROMATIC CARBOXY DIAMINE | CELANESE CORPORATION (US) | 1984-06-05 | — | — | US | disclosed |
| EP-0095348-A2 | High molecular weight polybenzimidazoles | CELANESE CORPORATION (US) | 1983-11-30 | — | — | EP | disclosed |
| US-4414383-A | High molecular weight polybenzimidazole preparation with phosphorus containing polymerization catalyst | CELANESE CORPORATION (US) | 1983-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217388-A1 | Phthalazine derivatives for treating inflammatory diseases | KDR, NR2E3, FLT1 | HTT 1544/4885KMT2A 2072/4885MEN1 3878/4885 |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | HTT 161/4885KMT2A 2309/4885MEN1 1992/4885 |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | BACE1, APP, PSEN1 | HTT 133/4885KMT2A 2294/4885MEN1 3795/4885 |
| US-20080293701-A1 | 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors | REN, AGTR1, AGTR2 | HTT 1710/4885KMT2A 2789/4885MEN1 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.